Compile Data Set for Download or QSAR
Report error Found 23 Enz. Inhib. hit(s) with all data for entry = 8454
TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM249390(US9464081, 22)
Affinity DataIC50: 6nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/11/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM249386(US9464081, 19)
Affinity DataIC50: 7nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/11/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM249383(US9464081, 16)
Affinity DataIC50: 7nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/11/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM249378(US9464081, 11)
Affinity DataIC50: 19nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/11/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM249389(US9464081, 23)
Affinity DataIC50: 24nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/11/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM249368(US9464081, 1)
Affinity DataIC50: 33nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/11/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM249369(US9464081, 2)
Affinity DataIC50: 35nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/11/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM249380(US9464081, 13)
Affinity DataIC50: 37nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/11/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM249382(US9464081, 15)
Affinity DataIC50: 43nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/11/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM249385(US9464081, 18)
Affinity DataIC50: 50nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/11/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM249374(US9464081, 7)
Affinity DataIC50: 56nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/11/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM249375(US9464081, 8)
Affinity DataIC50: 59nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/11/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM249381(US9464081, 14)
Affinity DataIC50: 63nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/11/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM249379(US9464081, 12)
Affinity DataIC50: 74nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/11/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM249377(US9464081, 10)
Affinity DataIC50: 78nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/11/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM249387(US9464081, 20)
Affinity DataIC50: 90nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/11/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM249373(US9464081, 6)
Affinity DataIC50: 99nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/11/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM249384(US9464081, 17)
Affinity DataIC50: 128nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/11/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM249372(US9464081, 5)
Affinity DataIC50: 253nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/11/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM249370(US9464081, 3)
Affinity DataIC50: 255nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/11/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM249376(US9464081, 9)
Affinity DataIC50: 356nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/11/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM249371(US9464081, 4)
Affinity DataIC50: 450nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/11/2017
Entry Details
US Patent

TargetComplement factor D(Human)
Novartis

US Patent
LigandPNGBDBM249388(US9464081, 21)
Affinity DataIC50: 1.80E+3nMpH: 7.5 T: 2°CAssay Description:Method 1: Recombinant human factor D (expressed in E. coli and purified using standard methods) at 10 nM concentration is incubated with test compoun...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/11/2017
Entry Details
US Patent